KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Progyny (PGNY) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Progyny (PGNY) over the last 8 years, with Q3 2025 value amounting to $134.0 million.

  • Progyny's Cash & Equivalents rose 4646.04% to $134.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $134.0 million, marking a year-over-year increase of 4646.04%. This contributed to the annual value of $162.3 million for FY2024, which is 6682.49% up from last year.
  • As of Q3 2025, Progyny's Cash & Equivalents stood at $134.0 million, which was up 4646.04% from $132.5 million recorded in Q2 2025.
  • Progyny's Cash & Equivalents' 5-year high stood at $170.6 million during Q2 2023, with a 5-year trough of $29.8 million in Q1 2021.
  • In the last 5 years, Progyny's Cash & Equivalents had a median value of $97.3 million in 2023 and averaged $103.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 6745.75% in 2021, then soared by 30009.27% in 2023.
  • Quarter analysis of 5 years shows Progyny's Cash & Equivalents stood at $91.4 million in 2021, then surged by 31.36% to $120.1 million in 2022, then dropped by 18.97% to $97.3 million in 2023, then surged by 66.82% to $162.3 million in 2024, then fell by 17.46% to $134.0 million in 2025.
  • Its Cash & Equivalents was $134.0 million in Q3 2025, compared to $132.5 million in Q2 2025 and $109.2 million in Q1 2025.